In The Lancet: Combining 2 anti-HER2 drugs may provide better preoperative breast cancer treatment

In an issue of The Lancet, an international research team in which VHIO participated, reports that a protocol adding lapatinib (Tykerb) to trastuzumab (Herceptin) was more effective than single-drug treatment with either drug in eliminating microscopic signs of cancer at the time the tumours were surgically removed.

To find out more about the results from this present NeoAdjuvant Lapatinib and/or Trastuzumab Treatment Optimization (NeoALTTO) pivotal study visit The Lancet.

For more information about VHIO´s participation please contact Amanda Wren, Communication Manager directly: Tel. +34 934893021, Email:

Related Posts

Privacy Preferences
When you visit our website, it may store information through your browser from specific services, usually in form of cookies. Here you can change your privacy preferences. Please note that blocking some types of cookies may impact your experience on our website and the services we offer.